PDF Archive search engine
Last database update: 17 February at 11:24 - Around 76000 files indexed.

Show results per page

Results for «nivolumab»:

Total: 4 results - 0.009 seconds

eNERGY NoteInfoConsentement V2.0 2017.11.06 100%

35RC16_9734_eNERGY NOTE D’INFORMATION Etude randomisée de phase III comparant l’association du nivolumab et de l’ipilimumab versus un doublet à base de carboplatine dans le traitement de première ligne du CBNPC avancé chez des patients PS 2 ou de plus de 70 ans eNERGY N° EudraCT :


eNERGY Protocole signe V2.0 2017.11.06 97%

ENERGY Trial Code Sponsor 35RC16_9734 / GFPC 08-2015 / BMS CA209-449 ENERGY Randomised phase III study testing nivolumab and ipilimumab versus a carboplatin based doublet in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer.


lsc-htbx-note-02022016 62%

It is important to highlight that 2016 will be a pivotal year for Heat Biologics, as the Company will report randomized Phase II data in bladder and lung cancer, and results from the DURGA trial combining HS-110 with Keytruda (nivolumab).


BTOG-2019-Programme-V7-Draft 49%

Keith Kerr (UK) Poster Oral Presentations Matthew Callister (UK) and Cindy Billingham (UK) Introduction - 7 minutes + 4 minutes discussion per speaker Psychological impact of low-dose CT screening in a ‘real world’ demonstration lung cancer screening pilot Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX) Modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune related adverse events in advanced non-small cell lung cancer (NSCLC) patients PD-L1 expression in resected non-small cell lung cancer;